MSP-1014
Psychedelic drug
From Wikipedia, the free encyclopedia
MSP-1014 is a serotonergic psychedelic which is under development for the treatment of major depressive disorder, other depressive disorders, and anxiety disorders.[3][4][5][1][2]
| Clinical data | |
|---|---|
| Other names | MSP1014; MSP-1014.OX |
| Routes of administration | Oral[1][2] |
| Drug class | Serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen |
It is a prodrug of psilocin similarly to psilocybin, and hence acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT2A receptor.[3][5][2][6]
The drug is under development by Mindset Pharma and Otsuka America Pharmaceutical.[3][4][5] As of January 2024, it is in phase 2 clinical trials for major depressive disorder and is in the preclinical stage of development for anxiety disorders and other depressive disorders.[3][4][5] The chemical structure of MSP-1014 does not yet seem to have been disclosed.[3][4] However, Mindset Pharma patented psilocin derivatives and prodrugs in 2022.[7]
See also
- Substituted tryptamine
- List of investigational hallucinogens and entactogens
- CT-4201, EB-002, and RE-109 (4-GO-DMT)
- Luvesilocin (4-GO-DiPT)
- MSP-2020
